Last-Resort cancer vaccine made available for AML and MDS patients

NCT ID NCT05593185

AVAILABLE Disease control Sponsor: Sellas Life Sciences Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This program provides galinpepimut-S, a cancer vaccine that aims to train the immune system to fight cancer cells, to individual patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have no other treatment options. It is for people who cannot join a clinical trial and have tried all standard therapies. The goal is to offer a potential treatment when nothing else is available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Galinpepimut-S (a cancer vaccine made from peptides to stimulate the immune system)
What this could lead to: If it works, this could offer a treatment option for patients with AML or MDS who have run out of standard therapies.
What could go wrong: This is an expanded access program, not a formal trial, so results are not systematically collected. The treatment may not work for everyone and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia hematopoietic and lymphoid system neoplasm myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROMES

More trials for these conditions

Other studies related to the condition(s) this trial covers.